Ultrasound Molecular Imaging
Seminar | April 17 | 12-1 p.m. | 106 Stanley Hall
Jonathan R. Lindner, MD, Oregon Health & Science University
Non-invasive in vivo molecular imaging technologies are uniquely poised to be able to spatially and temporally evaluate vascular adaptations to disease and the impact of new therapies. For ultrasound molecular imaging, nanoscale or microbubble ultrasound contrast agents have been developed that are targeted to disease by virtue of either surface conjugation of ligands or changes in their shell composition. Detection of these agents relies on the production and reception of non-linear signals produced during stable or inertial cavitation. The design of molecular imaging agents has involved biologic mimicry such as the use of catch bond ligands, long tether arms, and multi-valency. Ultrasound molecular imaging technologies have been used to study vascular changes in various forms of atherosclerotic and ischemic cardiovascular disease by studying the vascular phenotype or other novel molecular or endothelial signal features. Agents have been targeted to endothelial activation, inflammation, platelet adhesion, and oxidative modification. This talk will review new developments in ultrasound molecular imaging techniques that are likely to have a substantial impact on the understanding of pathophysiology, the development of new therapies, or diagnosis of disease in patients. The discussion will also include a discussion of how these different approaches may play a role to solve current clinical deficiencies.